Skip to search formSkip to main contentSkip to account menu

rolapitant

Known as: 1,7-diazaspiro(4.5)decan-2-one, 8-(((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-, (5S,8S)- 
National Institutes of Health

Related topics

Related topics

4 relations
Breast Cancer Resistance Protein Inhibitors [MoA]rolapitant 90 MG Oral Tablet [Varubi]rolapitant hydrochloride

Narrower (1)

Varubi

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Rolapitant Is a Reversible Inhibitor of CYP2D6
Rolapitant [(Varubi), 5S,8S)-8-[[(1R)-1-[3,5 bis(trifluoromethyl phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one… 
2018
2018
Effects of Rolapitant Administered Intravenously on the Pharmacokinetics of a Modified Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan) in Healthy Subjects
Rolapitant is a selective, long‐acting neurokinin‐1 receptor antagonist, approved in the United States and Europe for prevention… 
2018
2018
Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment
Rolapitant is a selective and long‐acting neurokinin‐1 receptor antagonist approved in an oral formulation in combination with… 
2017
2017
Rolapitant Absolute Bioavailability and PET Imaging Studies in Healthy Adult Volunteers
Rolapitant, a selective, long‐acting neurokinin‐1 (NK‐1) receptor antagonist, demonstrated efficacy in preventing chemotherapy… 
Review
2017
Review
2017
Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy
ABSTRACT Introduction: Five NK-1 RA formulations are commercially available to treat the delayed phase of chemotherapy-induced… 
2016
2016
Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers.
222 Background: Rolapitant (VARUBI) is a selective, long-acting neurokinin-1 receptor antagonist (RA) for the prevention of CINV… 
2015
2015
Rolapitant for the treatment of chemotherapy-induced nausea and vomiting
Chemotherapy-induced nausea and vomiting is a significant clinical issue which affects patient’s quality of life and treatment… 
2015
2015
Advances in the Management of Chemotherapy-Induced Nausea and Vomiting: New Data From Recent and Ongoing Trials.
Chemotherapy-induced nausea and vomiting (CINV) is among the most feared and debilitating adverse events experienced by cancer… 
2014
2014
Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist.
e20690 Background: Rolapitant is a potent, highly selective, competitive and long acting NK-1 receptor antagonist in development… 
2014
2014
Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy…
9633 Background: Rolapitant is a highly selective competitive long acting NK-1 receptor antagonist that demonstrated efficacy in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)